TY - JOUR T1 - Anti-inflammatory profile of paricalcitol in kidney transplant recipients JO - Nefrología (English Edition) T2 - AU - Donate-Correa,Javier AU - Henríquez-Palop,Fernando AU - Martín-Núñez,Ernesto AU - Hernández-Carballo,Carolina AU - Ferri,Carla AU - Pérez-Delgado,Nayra AU - Muros-de-Fuentes,Mercedes AU - Mora-Fernández,Carmen AU - Navarro-González,Juan F. SN - 20132514 M3 - 10.1016/j.nefroe.2017.11.010 DO - 10.1016/j.nefroe.2017.11.010 UR - https://revistanefrologia.com/en-anti-inflammatory-profile-paricalcitol-in-kidney-articulo-S2013251417301943 AB - Background and objectivesParicalcitol, a selective vitamin D receptor activator, is used to treat secondary hyperparathyroidism in kidney transplant patients. Experimental and clinical studies in non-transplant kidney disease patients have found this molecule to have anti-inflammatory properties. In this exploratory study, we evaluated the anti-inflammatory profile of paricalcitol in kidney-transplant recipients. MethodsThirty one kidney transplant recipients with secondary hyperparathyroidism completed 3 months of treatment with oral paricalcitol (1μg/day). Serum concentrations and gene expression levels of inflammatory cytokines in peripheral blood mononuclear cells were analysed at the beginning and end of the study. ResultsParicalcitol significantly decreased parathyroid hormone levels with no changes in calcium and phosphorous. It also reduced serum concentrations of interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) by 29% (p<0.05) and 9.5% (p<0.05) compared to baseline, respectively. Furthermore, gene expression levels of IL-6 and TNF-α in peripheral blood mononuclear cells decreased by 14.1% (p<0.001) and 34.1% (p<0.001), respectively. The ratios between pro-inflammatory cytokines (TNF-α and IL-6) and anti-inflammatory cytokines (IL-10), both regarding serum concentrations and gene expression, also experienced a significant reduction. ConclusionsParicalcitol administration to kidney transplant recipients has been found to have beneficial effects on inflammation, which may be associated with potential clinical benefits. ER -